Biosimilars, Contract Manufacturing, Licensed Products

Rovi is heavily invested in research and development (R&D), viewing it as a critical engine for future growth. The company focuses on creating innovative pharmaceutical products, including a diverse portfolio of both proprietary and licensed medications. Among its key offerings is a low-molecular-weight heparin, which has been developed in-house and represents a significant aspect of Rovi's product line. The company also sees substantial growth potential in the biosimilars market, which is valued at over 1 billion euros in Europe. Rovi's commitment to R&D is reflected in its financial investments, with a reported 24.9 million euros allocated to R&D expenses in 2023.

In addition to its R&D efforts, Rovi operates a Contract Development and Manufacturing Organization (CDMO) with high production capacity across four manufacturing plants. This capability allows Rovi to produce prefilled syringes and oral solid forms efficiently. The company maintains a strong presence in the low molecular weight heparin market through strategic alliances with international partners, further enhancing its global reach. Rovi's diversified portfolio and strategic focus on innovation position it well within the pharmaceutical industry, as evidenced by its operating revenue and sales figures for 2023.

Spain

Rovi is a specialized pharmaceutical company engaged in the research, development, manufacture and marketing of pharmaceutical products. Their operations encompass the marketing of both their own and licensed products and the provision of services, such as production, filling and packaging, to other companies.

Rovi

Company Details